Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 17 studies | 28% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 201.63 | 575 / 578 | 81% | 8.60 | 938 / 1155 |
prostate | 86% | 55.27 | 211 / 245 | 70% | 3.85 | 351 / 502 |
uterus | 82% | 40.49 | 139 / 170 | 72% | 7.42 | 330 / 459 |
thymus | 88% | 66.98 | 574 / 653 | 63% | 10.03 | 383 / 605 |
liver | 92% | 64.64 | 207 / 226 | 60% | 4.46 | 242 / 406 |
breast | 79% | 44.64 | 362 / 459 | 64% | 6.18 | 719 / 1118 |
kidney | 63% | 37.03 | 56 / 89 | 77% | 6.00 | 693 / 901 |
skin | 56% | 23.08 | 1014 / 1809 | 83% | 15.44 | 392 / 472 |
stomach | 82% | 47.52 | 294 / 359 | 57% | 3.56 | 163 / 286 |
bladder | 71% | 58.29 | 15 / 21 | 56% | 4.48 | 280 / 504 |
intestine | 72% | 82.64 | 700 / 966 | 54% | 3.09 | 282 / 527 |
brain | 72% | 51.68 | 1911 / 2642 | 45% | 1.73 | 318 / 705 |
ovary | 67% | 27.66 | 120 / 180 | 37% | 1.51 | 161 / 430 |
lymph node | 0% | 0 | 0 / 0 | 100% | 66.02 | 29 / 29 |
spleen | 100% | 864.77 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 87% | 67.44 | 1048 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 15.16 | 39 / 45 |
peripheral blood | 84% | 2057.86 | 780 / 929 | 0% | 0 | 0 / 0 |
pancreas | 13% | 3.90 | 41 / 328 | 68% | 5.96 | 121 / 178 |
adrenal gland | 34% | 11.01 | 89 / 258 | 37% | 1.89 | 85 / 230 |
esophagus | 47% | 18.30 | 683 / 1445 | 19% | 0.82 | 35 / 183 |
blood vessel | 47% | 27.05 | 623 / 1335 | 0% | 0 | 0 / 0 |
heart | 40% | 14.80 | 348 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 34% | 1.90 | 27 / 80 |
muscle | 7% | 1.94 | 57 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0031640 | Biological process | killing of cells of another organism |
GO_0001913 | Biological process | T cell mediated cytotoxicity |
GO_0006508 | Biological process | proteolysis |
GO_0045087 | Biological process | innate immune response |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0008236 | Molecular function | serine-type peptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | GZMM |
Protein name | Granzyme M Granzyme M (EC 3.4.21.-) (Met-1 serine protease) (Hu-Met-1) (Met-ase) (Natural killer cell granular protease) |
Synonyms | MET1 |
Description | FUNCTION: Cleaves peptide substrates after methionine, leucine, and norleucine. Physiological substrates include EZR, alpha-tubulins and the apoptosis inhibitor BIRC5/Survivin. Promotes caspase activation and subsequent apoptosis of target cells. . |
Accessions | ENST00000592501.5 P51124 ENST00000264553.6 U3KQV5 |